GlaxoSmithKline PLC (GSK) Downgraded to Underweight at Morgan Stanley
Several other brokerages also recently weighed in on GSK. ValuEngine downgraded shares of GlaxoSmithKline PLC from a buy rating to a hold rating in a research note on Friday, June 2nd. J P Morgan Chase & Co reissued a neutral rating on shares of GlaxoSmithKline PLC in a research report on Friday, June 16th. TheStreet raised shares of GlaxoSmithKline PLC from a c rating to a b rating in a research report on Friday, May 19th. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a buy rating to a hold rating in a research report on Friday, July 21st. Finally, Citigroup Inc. downgraded shares of GlaxoSmithKline PLC from a buy rating to a neutral rating in a research report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $46.00.
Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down 0.25% during trading on Friday, reaching $40.05. 2,015,586 shares of the company traded hands. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.54. The company has a market capitalization of $97.88 billion, a price-to-earnings ratio of 39.81 and a beta of 1.03. The firm’s 50 day moving average price is $40.01 and its 200-day moving average price is $41.81.
GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The firm had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. Equities analysts anticipate that GlaxoSmithKline PLC will post $2.86 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://theolympiareport.com/2017/09/09/glaxosmithkline-plc-gsk-downgraded-to-underweight-at-morgan-stanley.html.
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a $0.491 dividend. This represents a $1.96 annualized dividend and a dividend yield of 4.90%. The ex-dividend date of this dividend is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 197.00%.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Intl Fcstone Inc. increased its holdings in shares of GlaxoSmithKline PLC by 151.2% in the 2nd quarter. Intl Fcstone Inc. now owns 38,057 shares of the pharmaceutical company’s stock valued at $1,641,000 after purchasing an additional 22,909 shares in the last quarter. Farmers National Bank increased its holdings in shares of GlaxoSmithKline PLC by 23.6% in the 2nd quarter. Farmers National Bank now owns 18,446 shares of the pharmaceutical company’s stock valued at $795,000 after purchasing an additional 3,521 shares in the last quarter. WFG Advisors LP increased its holdings in shares of GlaxoSmithKline PLC by 16.7% in the 2nd quarter. WFG Advisors LP now owns 6,290 shares of the pharmaceutical company’s stock valued at $271,000 after purchasing an additional 898 shares in the last quarter. Oak Associates Ltd. OH increased its holdings in shares of GlaxoSmithKline PLC by 10.0% in the 2nd quarter. Oak Associates Ltd. OH now owns 311,300 shares of the pharmaceutical company’s stock valued at $13,423,000 after purchasing an additional 28,220 shares in the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of GlaxoSmithKline PLC by 7.6% in the 2nd quarter. Cetera Investment Advisers now owns 25,975 shares of the pharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 1,836 shares in the last quarter. Institutional investors and hedge funds own 9.28% of the company’s stock.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.